1. France Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Adocia SA

Adocia SA

2.34
EUR
-0.02
(-0.68%)
95.02MMarket Cap
Mar 03Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.9
0.11
5.52
3.28
2.84
6.85
0.31
0.12
0.2
1.43
0.15
0.63
0.08
- -
Basic EPS, GAAP
-0.69
-3.33
1.88
-1.15
-1.25
1.1
-2.68
-3.34
-3.22
-0.86
-1.5
-0.63
-0.93
- -
Free Cash Flow per Basic Share
-1.81
4.85
-1.12
-3.1
-3.53
0.8
-1.68
-3.16
-2.78
-1.89
-0.36
-1.07
-0.38
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
3.1
0.4
6.88
6.23
5.34
6.62
4.04
0.91
-1.91
-1.49
-0.49
-0.2
0.08
-0.2
Tangible Book Value per Share
3.1
0.4
6.88
6.23
5.33
6.61
4.03
0.9
-1.91
-1.49
-0.49
-0.2
0.08
-0.2
Basic Weighted Avg Shares
6
6
7
7
7
7
7
7
7
8
14
15
18
15
Sales/Revenue/Turnover
6
1
37
22
19
47
2
1
1
11
2
9
1
- -
Operating Margin (%)
-76.95
-2,437.5
27.35
-35.58
-42.01
20.49
-1,027.53
-2,514.74
-1,341.07
-14.82
-662.51
-79.41
-1,068.68
- -
Depreciation Expense
- -
- -
1
1
1
1
1
1
1
1
- -
- -
1
- -
Net Income, GAAP
-4
-21
13
-8
-9
8
-19
-23
-23
-7
-21
-9
-17
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
35.24
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-76.81
-2,942.47
33.98
-35.09
-43.92
16.07
-868.08
-2,773.37
-1,575.76
-60.29
-984.28
-100
-1,124.81
- -
Working Capital
20
31
66
42
36
46
41
26
-2
1
- -
2
4
2
LT Debt
2
1
1
6
6
5
19
25
18
18
11
9
6
9
Total Equity
19
3
47
43
37
46
28
6
-14
-13
-7
-3
1
-3
Return on Invested Capital (%)
- -
- -
- -
- -
- -
12.82
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
15.84
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-20.37
-191.5
50.66
-17.57
-21.48
18.41
-50.35
-135.71
- -
- -
- -
- -
- -
- -

Capital Structure

EUR

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
ST Debt
2
3
3
LT Borrowings
5
3
2
LT Finance Leases
7
7
7
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
14
15
16
Market Capitalization
163
124
95

Working Capital

EUR

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
Total Current Assets
20
19
22
Cash, Cash Equivalents & STI
13
10
8
Accounts Receivable, Net
- -
- -
9
Inventories
- -
- -
- -
Total Current Liabilities
20
21
21
Payables & Accruals
- -
- -
- -
ST Debt
2
3
3
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-68.93%
-114.9%
-148.27%
Free Cash Flow
-9.5%
10.6%
-57.09%
Net Income, GAAP
-50.59%
31.32%
78%
Sales/Revenue/Turnover
86.72%
186.51%
-84.18%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
2
2024
- -
- -
9
2025
- -
- -
1

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-1.5
2024
- -
- -
-0.63
2025
- -
- -
-0.93

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Olivier Soula
Full Time Employees
82
Sector
Health technology
Industry
Pharmaceuticals: major
Address
115 Avenue Lacassagne Lyon AR France 69003
IPO Date
Feb 17, 2012
Website
adocia.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Adocia SA (ADOC.PA) is a clinical-stage biotechnology company that develops innovative formulations of approved therapeutic proteins and peptides, as well as novel cell therapy approaches, primarily for the treatment of diabetes and obesity; its proprietary platforms include BioChaperone for new-generation insulins and hormone combinations, AdoShell for immunoprotective islet cell transplantation, AdOral for oral peptide delivery, and AdoGel for long-acting drug delivery. Key products in its diversified pipeline encompass BioChaperone Lispro, an ultra-rapid prandial insulin formulation licensed to Tonghua Dongbao for China and select Asian markets and ready for Phase 3 trials in the US and Europe upon partnership; BioChaperone Combo, a fixed-ratio co-formulation of insulin glargine and lispro for type 2 diabetes; M1Pram and BioChaperone LisPram, pramlintide-insulin combinations with Sanofi for glycemic control and weight management in obese diabetic patients; AdoShell Islets, a retrievable hydrogel implant for type 1 diabetes cell therapy; AdOral Sema, an oral semaglutide; and AdoGel Sema, a steady-release injectable semaglutide hydrogel, with additional assets like BioChaperone GLP-1 Amylin in development. Founded in 2005 by the Soula family and headquartered in Lyon, France, the company targets patients with type 1 and type 2 diabetes and obesity globally through partnerships, with operations centered in Europe and licensing in Asia. Recent developments include a €9.7 million private placement in February 2025 led by Armistice Capital and existing shareholders, extending cash runway to Q2 2026; a US$10 million milestone from Tonghua Dongbao in 2025 following positive Phase 3 topline results for ultra-rapid BioChaperone Lispro (THDB0206) in type 1 diabetes; €10 million upfront from Sanofi for exclusive negotiation rights on M1Pram, with ongoing partnership discussions; a new patent filing in November 2025 for the AdoXLong long-acting peptides platform alongside BioChaperone updates; and oral presentations on AdoShell and BioChaperone at EASD, ESB, and PODD 2025 meetings.